Sign in
Back
Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report
Journal article   Peer reviewed

Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report

Hisham A Badreldin, Jessica Rimsans, Jean M Connors and Stephen D Wiviott
Catheterization and cardiovascular interventions, Vol.91(3), pp.E17-E20
15/02/2018
DOI: https://doi.org/10.1002/ccd.27368
PMID: 29068112

Abstract

Anticoagulants - administration & dosage Anticoagulants - adverse effects Antithrombins - administration & dosage Blood Coagulation - drug effects Drug Administration Schedule Drug Substitution Fatal Outcome Fibrinolytic Agents - administration & dosage Heparin - administration & dosage Heparin - adverse effects Hirudins - administration & dosage Humans Infusions, Intravenous Male Middle Aged Peptide Fragments - administration & dosage Pulmonary Embolism - blood Pulmonary Embolism - diagnosis Pulmonary Embolism - drug therapy Recombinant Proteins - administration & dosage Thrombocytopenia - blood Thrombocytopenia - chemically induced Thrombocytopenia - diagnosis Thrombolytic Therapy Tissue Plasminogen Activator - administration & dosage Tomography, X-Ray Computed Treatment Outcome
In patients with submassive pulmonary embolism, the use of catheter-directed thrombolysis (CDT), using low-dose alteplase is associated with improvement in overall hemodynamics. The data for use of CDT in patients with heparin-induced thrombocytopenia are limited. We report a case of CDT in a patient with HIT using bivalirudin anticoagulation. Data of the use of bivalirudin and argatroban for systemic anticoagulation with CDT are limited.

Metrics

1 Record Views

Details